NASDAQ:DWTX Dogwood Therapeutics (DWTX) Stock Price, News & Analysis $1.79 -0.02 (-1.10%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.66 -0.13 (-7.26%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Dogwood Therapeutics Stock (NASDAQ:DWTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dogwood Therapeutics alerts:Sign Up Key Stats Today's Range$1.77▼$1.8650-Day Range$1.34▼$3.2252-Week Range$1.28▼$9.50Volume21,270 shsAverage Volume92,470 shsMarket Capitalization$60.20 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential. Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients. Its preclinical pipeline includes antibody and protein candidates targeting key inflammatory and fibrotic pathways. In addition to cardiovascular indications, the company is evaluating opportunities in liver and renal fibrosis, with plans to advance multiple programs into IND‐enabling studies over the coming year. Founded in 2021 and headquartered in Vancouver, British Columbia, Dogwood Therapeutics also maintains research operations in Boston, Massachusetts. The company works in collaboration with academic institutions and clinical research organizations across North America to support its development efforts. Led by an experienced management team with backgrounds in biologics discovery and cardiovascular drug development, Dogwood is positioning itself to address significant unmet needs in fibrotic disease.AI Generated. May Contain Errors. Read More Dogwood Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreDWTX MarketRank™: Dogwood Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 352nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingDogwood Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialDogwood Therapeutics has a consensus price target of $12.00, representing about 570.4% upside from its current price of $1.79.Amount of Analyst CoverageDogwood Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Dogwood Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Dogwood Therapeutics are expected to grow in the coming year, from ($0.55) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dogwood Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dogwood Therapeutics is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDogwood Therapeutics has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Dogwood Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.38% of the float of Dogwood Therapeutics has been sold short.Short Interest Ratio / Days to CoverDogwood Therapeutics has a short interest ratio ("days to cover") of 0.96, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Dogwood Therapeutics has recently increased by 169.46%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDogwood Therapeutics does not currently pay a dividend.Dividend GrowthDogwood Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.62 News SentimentDogwood Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Dogwood Therapeutics this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added Dogwood Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dogwood Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.20% of the stock of Dogwood Therapeutics is held by insiders.Percentage Held by Institutions9.05% of the stock of Dogwood Therapeutics is held by institutions.Read more about Dogwood Therapeutics' insider trading history. Receive DWTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dogwood Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DWTX Stock News HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), Century Therapeutics (IPSC)May 20, 2026 | theglobeandmail.comDogwood Therapeutics Inc Ordinary Shares DWTXMay 19, 2026 | morningstar.comMYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.May 24 at 1:00 AM | Profits Run (Ad)Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Commencement of Halneuron Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension StudyMay 18, 2026 | finanznachrichten.deDogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension StudyMay 18, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Dogwood Therapeutics (DWTX) and US Physical Therapy (USPH)May 17, 2026 | theglobeandmail.comDogwood Therapeutics Announces First Quarter 2026 Financial ResultsMay 14, 2026 | globenewswire.comDogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026May 7, 2026 | globenewswire.comSee More Headlines DWTX Stock Analysis - Frequently Asked Questions How have DWTX shares performed this year? Dogwood Therapeutics' stock was trading at $4.16 at the beginning of the year. Since then, DWTX shares have decreased by 57.0% and is now trading at $1.79. How were Dogwood Therapeutics' earnings last quarter? Dogwood Therapeutics, Inc (NASDAQ:DWTX) announced its quarterly earnings data on Thursday, May, 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.07. When did Dogwood Therapeutics' stock split? Dogwood Therapeutics shares reverse split before market open on Wednesday, October 9th 2024.A 1-25 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Dogwood Therapeutics IPO? Dogwood Therapeutics (DWTX) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. How do I buy shares of Dogwood Therapeutics? Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/14/2026Today5/24/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 DWTX's financial health is in the Yellow zone, according to TradeSmith. DWTX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DWTX CIK1818844 Webwww.dwtx.com Phone(866) 620-8655FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Dogwood Therapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+570.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($10.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-108.57% Return on Assets-30.28% Debt Debt-to-Equity RatioN/A Current Ratio5.86 Quick Ratio2.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.40 per share Price / Book0.75Miscellaneous Outstanding Shares33,630,000Free Float33,563,000Market Cap$60.20 million OptionableN/A Beta1.68 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:DWTX) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredJune 12: Elon Musk’s “Day-One Retirement Plan.”SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dogwood Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Dogwood Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
